Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
BBLG 
Bone Biologics Corp (BBLG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: BBLG (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $22.5
1 Year Target Price $22.5
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -76.27% | Avg. Invested days 22 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.50M USD | Price to earnings Ratio - | 1Y Target Price 22.5 |
Price to earnings Ratio - | 1Y Target Price 22.5 | ||
Volume (30-day avg) 1 | Beta 1.28 | 52 Weeks Range 3.42 - 22.20 | Updated Date 06/30/2025 |
52 Weeks Range 3.42 - 22.20 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -23.04 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -77.73% | Return on Equity (TTM) -129.48% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -244211 | Price to Sales(TTM) - |
Enterprise Value -244211 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.13 | Shares Outstanding 545173 | Shares Floating 537318 |
Shares Outstanding 545173 | Shares Floating 537318 | ||
Percent Insiders 0.12 | Percent Institutions 1.1 |
Analyst Ratings
Rating 1 | Target Price 22.5 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Bone Biologics Corp
Company Overview
History and Background
Bone Biologics Corp (BBLG) is a biotechnology company focused on bone regeneration technology. It was founded with the goal of developing and commercializing novel osteobiologic products for spinal fusion and fracture healing.
Core Business Areas
- Osteobiologics Development: Focused on the development and commercialization of NBMTM (NELL-1 based matrix), a recombinant human protein therapeutic for bone regeneration.
Leadership and Structure
The leadership team consists of experienced executives in biotechnology and orthopedics. The company structure is typical of a small, development-stage biotechnology firm, with emphasis on research, clinical development, and regulatory affairs.
Top Products and Market Share
Key Offerings
- NELL-1 based matrix (NBMTM): NELL-1 is a recombinant human protein therapeutic designed to promote bone regeneration and spinal fusion. Currently in clinical development, it does not yet have market share. Competitors include Medtronic (MDT), Stryker (SYK), and NuVasive (NUVA), which offer bone graft substitutes and biologics.
Market Dynamics
Industry Overview
The orthopedic biologics market is experiencing growth driven by an aging population, increasing prevalence of spinal disorders, and demand for minimally invasive surgical techniques. The market is competitive, with both large and small companies vying for market share.
Positioning
Bone Biologics Corp is positioned as an innovator in bone regeneration, leveraging its proprietary NELL-1 technology. Its success depends on clinical trial outcomes and regulatory approvals.
Total Addressable Market (TAM)
The total addressable market for bone graft substitutes and biologics is estimated to be billions of dollars annually. BBLG is positioned to capture a portion of this market if NBMTM is successfully commercialized.
Upturn SWOT Analysis
Strengths
- Proprietary NELL-1 technology
- Potential for superior bone regeneration compared to existing products
- Experienced management team
Weaknesses
- Limited financial resources
- Reliance on clinical trial success
- Lack of commercialized products
- High burn rate
Opportunities
- Partnerships with larger orthopedic companies
- Expansion into new indications for NELL-1
- Favorable regulatory environment for biologics
- Growing demand for minimally invasive spinal fusion procedures
Threats
- Clinical trial failures
- Competition from established players
- Regulatory hurdles
- Difficulty securing funding
Competitors and Market Share
Key Competitors
- MDT
- SYK
- NUVA
Competitive Landscape
Bone Biologics Corp faces intense competition from established orthopedic companies with significantly greater resources. Its competitive advantage lies in its proprietary NELL-1 technology.
Growth Trajectory and Initiatives
Historical Growth: Growth has been primarily in R&D spending and clinical trial activity.
Future Projections: Future growth depends on successful clinical trials, regulatory approvals, and commercialization of NBMTM. Analyst estimates are highly speculative at this stage.
Recent Initiatives: Recent initiatives include advancing clinical trials for NBMTM and securing additional funding.
Summary
Bone Biologics Corp is a high-risk, high-reward biotechnology company with a promising bone regeneration technology. The company's success hinges on the outcome of clinical trials and its ability to secure funding. It faces strong competition from established players in the orthopedic market and is currently in a highly developmental stage without revenue. Investors need to closely monitor clinical trial data and the company's cash position.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC filings
- Industry reports
- Analyst reports (when available)
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and may not be entirely accurate or complete. Investment decisions should be made based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bone Biologics Corp
Exchange NASDAQ | Headquaters Burlington, MA, United States | ||
IPO Launch date 2016-03-31 | CEO & President Mr. Jeffrey Frelick | ||
Sector Healthcare | Industry Medical Devices | Full time employees 2 | Website https://www.bonebiologics.com |
Full time employees 2 | Website https://www.bonebiologics.com | ||
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's lead medical device NELL-1/DBM, an osteopromotive recombinant protein that provides target-specific control over bone regeneration. It also develops NELL-1/DBM fusion device used in lumbar spinal fusion. The company's NELL-1 platform technology used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.